(Total Views: 442)
Posted On: 09/15/2020 9:57:09 AM
Post# of 208
In my opinion,TSOI is working its way on to a super vaccine. All vaccines have something in commom that their job is to educate your immune system. So vaccines present foreign material to a person's immune system and lot of vaccines rely on different kind of boosters or adjuvants or carriers and so forth. But TSOI's STEMVACS2 relies on the body's natural cells to perform that job. The body has group of cells called Dendritic Cells and they are nature's most potent antigen presenting cells... so they were designed to pickup foreign material and present it to your immune system and basically educate or teach your immune system so that it can eradicate them . It does not matter whether the foreign material comes from a cell that has lost its ability to control growth meaning a tumor or from a bacteria or a virus. If its foreign material, then the dendritic cell will educate the body's immune system to eradicate the virus.
So for example TSOI could put a spike protein SARS-COV2 or other foreign material or other antigens to load those messages into the dendritic cells and inject them by the millions/billions into patients.
so that you are almost carrying almost like the post office as you are carrying th most important information but you are not relying on some pigeon or pony express but you are using the best system;
That is what TSOI STEMVACS2 technology is based on the ability to manufacture a specific kind of dendritic cell and expand those cells into the many millions/billions and then use those cells for treatment.
TSOI deploys STEMVACS2 into COVID-19 patient by simply choosing a viral antigen as the messenger or the information rather than a tumor antigen.
Almost all of of the biotech companies in this COVID-19 space are doing some kind of repurposing recently but fortunately TSOI has been already working on SARS/MERS since 2 years. Now TSOI is in the process of initiating series of PHASE II Clinical trials some in COVID-19 and some in CANCER setting.
Since TSOI has already developed the cancer antigen which is being delivered by these dendritic cells so TSOI intends to re-purpose the same to COVID-19 as its antigen is plug and play. So TSOI can manufacture a different antigen cassette and drop that cassette into STEMVACS DENDRITIC CELL and move forward into clinical trials.
One of the convenient things is that TSOI have been already able to do STEMVACS2 on humans in PHASE 1 Clinical trial already to prove the safety profile of DC in cancer patients. So there is opporunity for TSOI to move pretty quickly. This COVID-19 could have been lot worse and there' no promise that the next pandemic that comes is going to be any easier. It could be more deadly and more infectious it could mutate at faster rate. I think TSOIs view is that there are patients out there for whom a really robust T-CEll response is necessary. So TSOI is not emphasizing much on the Anti Bodies much because that is not going to get the durable protection, multi-year protection. Nobody wants this pandemic or future pandemic to be a seasonal problem as it starts to become incalculable both on the economy and on the impact on the human health. Clearly TSOI is focused on using the power of STEMVACS2 DENDRITIC CELLS to get very strong T-cell response beacuse thats where you can get your multi year protection from COVID-19.
So for example TSOI could put a spike protein SARS-COV2 or other foreign material or other antigens to load those messages into the dendritic cells and inject them by the millions/billions into patients.
so that you are almost carrying almost like the post office as you are carrying th most important information but you are not relying on some pigeon or pony express but you are using the best system;
That is what TSOI STEMVACS2 technology is based on the ability to manufacture a specific kind of dendritic cell and expand those cells into the many millions/billions and then use those cells for treatment.
TSOI deploys STEMVACS2 into COVID-19 patient by simply choosing a viral antigen as the messenger or the information rather than a tumor antigen.
Almost all of of the biotech companies in this COVID-19 space are doing some kind of repurposing recently but fortunately TSOI has been already working on SARS/MERS since 2 years. Now TSOI is in the process of initiating series of PHASE II Clinical trials some in COVID-19 and some in CANCER setting.
Since TSOI has already developed the cancer antigen which is being delivered by these dendritic cells so TSOI intends to re-purpose the same to COVID-19 as its antigen is plug and play. So TSOI can manufacture a different antigen cassette and drop that cassette into STEMVACS DENDRITIC CELL and move forward into clinical trials.
One of the convenient things is that TSOI have been already able to do STEMVACS2 on humans in PHASE 1 Clinical trial already to prove the safety profile of DC in cancer patients. So there is opporunity for TSOI to move pretty quickly. This COVID-19 could have been lot worse and there' no promise that the next pandemic that comes is going to be any easier. It could be more deadly and more infectious it could mutate at faster rate. I think TSOIs view is that there are patients out there for whom a really robust T-CEll response is necessary. So TSOI is not emphasizing much on the Anti Bodies much because that is not going to get the durable protection, multi-year protection. Nobody wants this pandemic or future pandemic to be a seasonal problem as it starts to become incalculable both on the economy and on the impact on the human health. Clearly TSOI is focused on using the power of STEMVACS2 DENDRITIC CELLS to get very strong T-cell response beacuse thats where you can get your multi year protection from COVID-19.
(0)
(0)Scroll down for more posts ▼
